Organon (OGN) Falls More Steeply Than Broader Market: What Investors Need to Know
Organon (OGN) closed at $6.23 in the latest trading session, marking a -2.5% move from the prior day.
Investors Heavily Search Organon & Co. (OGN): Here is What You Need to Know
Zacks.com users have recently been watching Organon (OGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
OGN's VTAMA Cream Shows Sleep Benefits in Pediatric Atopic Dermatitis
Organon reports Phase 3 data showing VTAMA improved sleep in children as young as two with atopic dermatitis, reinforcing its dermatology push.
Organon: Revenue Decline, Margin Pressure, And Strategic Uncertainty
Organon reported a disappointing Q4, with revenue down 5% YoY and significant weakness in women's health. Shares are heavily oversold, but I maintain a Hold rating due to strategic uncertainty and lack of near-term catalysts. Management prioritizes debt reduction and margin preservation over growth, with no revenue improvement expected through 2026.
Organon Q4 Earnings Review: Poor Results Trigger Predictable Sell-Off
Organon reported disappointing 2025 results, with revenues down 3% and no growth expected in 2026. OGN faces potentially terminal declines in established brands, flat biosimilar growth, and underwhelming Women's Health performance, all compounded by ~$8bn in net debt. The dividend was slashed last year to $0.02/quarter, a yield of now ~1%, with capital allocation constrained by high-interest expenses and limited M&A capacity.
Organon (OGN) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Organon (OGN) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Organon & Co. (OGN) Q4 2025 Earnings Call Transcript
Organon & Co. (OGN) Q4 2025 Earnings Call Transcript
Organon (OGN) Misses Q4 Earnings and Revenue Estimates
Organon (OGN) came out with quarterly earnings of $0.63 per share, missing the Zacks Consensus Estimate of $0.73 per share. This compares to earnings of $0.9 per share a year ago.
Organon (OGN) Stock Falls Amid Market Uptick: What Investors Need to Know
Organon (OGN) concluded the recent trading session at $8.2, signifying a -3.98% move from its prior day's close.
Organon Completes Divesture of JADA System to Laborie Medical
OGN completes JADA System divestiture to Laborie for up to $465M, bolstering its balance sheet and backing debt reduction to fund women's health growth.
Organon (OGN) Outperforms Broader Market: What You Need to Know
Organon (OGN) concluded the recent trading session at $9.59, signifying a +1.37% move from its prior day's close.
Organon Secures FDA Approval Extending NEXPLANON Use to Five Years
OGN wins FDA approval to extend NEXPLANON use to five years, backed by trials showing no pregnancies and strong efficacy across body weights.
